The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) drugs in development market research report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) by 18 companies/universities/institutes. The top development phase for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) is preclinical with eight drugs in that stage. The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline has 15 drugs in development by companies and five by universities/ institutes. Some of the companies in the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline products market are: Poxel, Viking Therapeutics and Centers of Biomedical Research Network.
The key targets in the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline products market include Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB), Mitochondrial Pyruvate Carrier (MPC), and Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2).
The key mechanisms of action in the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline product include Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB) Agonist with two drugs in Phase I. The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline products include six routes of administration with the top ROA being Oral and six key molecule types in the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline products market including Small Molecule, and Cell Therapy.
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) overview
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of adrenoleukodystrophy (adrenomyeloneuropathy/Schilder-Addison complex). Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in the gene that tells the body to create lipoproteins. Symptoms include curvature of the spine, muscle weakness, and decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
For a complete picture of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
